INNATE PHARMA : Outcome of Annual General Meeting of June 2, 2016
03 Juin 2016 - 7:04AM
Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces the
results of the voting by shareholders at the Annual General Meeting
("AGM") which took place on June 2, 2016, in Marseille, France. All
resolutions were voted in accordance with the management's
recommendations.
Total of 24,290,258 votes were cast out of a
total of 53,877,079 shares with voting rights, representing a
quorum of 45.084%.
Details of the votes are available on the
Company's website, in the investors' room
(http://www.innate-pharma.com/AGMdocuments).
The 2015 Activity Report
and the 2015 Reference Document of the
Company are available on its website.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
Innate Pharma specializes in immuno-oncology, a
new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells.
The Company has pioneered the development of
antibodies that block inhibitory checkpoint receptors on NK cells.
Today, Innate Pharma has three first-in-class antibodies in
clinical development in immuno-oncology and a pipeline of
preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into
alliances with leaders in the biopharmaceutical industry such as
AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma had
122 employees as at March 31, 2016. The company is listed on
Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical Information about Innate
Pharma shares:
ISIN code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website (http://www.amf-france.org) or on Innate Pharma's
website.
This press release and the information
contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate
Pharma in any country.
For additional information, please
contact:
Innate
Pharma |
Press
Contacts |
Laure-Hélène Mercier
Director, Investor Relations |
ATCG Press (France) Marie Puvieux |
Tel.: +33 (0)4 30 30 30
87 |
Mob: +33 (0)6 10 54 36 72 |
investors@innate-pharma.com |
presse@atcg-partners.com |
|
Consilium Strategic Communications (ROW) |
|
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Hendrik
Thys |
|
Tel.: +44 (0)20 3709 5700 |
|
InnatePharma@consilium-comms.com |
PR in English http://hugin.info/155662/R/2017751/748781.pdf
HUG#2017751
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024